Abstract: Parkinson disease (PD) is the second most common neurodegenerative disorder after Alzheimer disease, severely impacting patients' quality of life and imposing a heavy burden on families and society. Conventional imaging techniques such as CT and MRI have limited value in the early diagnosis and differential diagnosis of PD. PET provides unique diagnostic advantages by enabling non-invasive, real-time assessment of structural and metabolic changes across brain regions. The authors review the research progress of the application of multiple molecular probe PET imaging in PD and parkinson syndrome.